Search
Filter Results
Displaying 491–500 of 800 for “retinitis clinical trial”
-
May 7, 2020
Foundation and Vision Partners Seek Biomedical Research Support from Congress during COVID-19 Crisis
Delays in Research Impacting Therapy Development
-
Jan 19, 2022
Foundation Fighting Blindness Promotes Jason Menzo to President and Chief Operating Officer
Noteworthy Foundation executive increases role within organization.
-
Oct 20, 2021
Opus Genetics Announces Two Key Leadership Appointments
Dr. Ash Jayagopal named Chief Scientific Officer and Mr. Joe Schachle appointed Chief Operating Officer.
-
Sep 13, 2022
Foundation Fighting Blindness Makes Key Appointments to Leadership Team
Several executives promoted to continue the advancement of the Foundation’s notable research and philanthropic efforts.
-
Jan 6, 2022
RD Fund Announces Series B Financing Behind SalioGen Therapeutics
Investment in new portfolio company furthering genetic medicine approaches for individuals affected by retinal degenerative diseases.
-
Investing in Cures Summit 2021
The 2021 Investing in Cures Summit (ICS) convenes key stakeholders of the Foundation Fighting Blindness and RD Fund to learn from the world’s leading industry, clinical and retinal science innovators poised to take emerging therapies across the finish line.
-
Mar 12, 2020
Seeing hope: Ledyard nonprofit focuses on rare retinal diseases
Sofia Priebe, 17, is legally blind. Her parents have started a nonprofit, Sofia Sees Hope, to raise funds for research into and awareness of the rare genetic disease Leber congenital amaurosis, which causes her blindness.
-
Alan Laties Career Development Program
The Alan Laties Career Development Program supports physicians’ and physician-scientists’ career development through a multi-level, tiered approach across the duration of their career. Each level represents a new “stage” in the career progression of a physician or physician-scientist, at a point when they can choose a clinical and/or research direction. The Foundation Fighting Blindness’ career development program includes funding support for clinicians, and medical residents in veterinarian studies in retinal degenerations.
-
Apr 30, 2018
ARVO 2018: Dr. Shannon Boye Reports on her Emerging Gene Therapy for LCA (GUCY2D)
Shannon Boye, PhD, University of Florida, talks about the advancement of her of gene therapy for Leber congenital amaurosis toward a clinical trial.